Mutual of America Capital Management LLC Decreases Stake in Pfizer Inc. (NYSE:PFE)

Mutual of America Capital Management LLC lowered its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 2.9% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 658,061 shares of the biopharmaceutical company's stock after selling 19,866 shares during the quarter. Mutual of America Capital Management LLC's holdings in Pfizer were worth $16,675,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Brighton Jones LLC raised its position in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after buying an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC grew its holdings in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after purchasing an additional 2,087 shares during the last quarter. Achmea Investment Management B.V. bought a new position in Pfizer during the 4th quarter valued at about $2,812,000. Madison Investment Advisors LLC bought a new position in Pfizer during the 4th quarter valued at about $5,360,000. Finally, Greatmark Investment Partners Inc. bought a new position in Pfizer during the 4th quarter valued at about $230,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Bank of America upped their price target on shares of Pfizer from $26.00 to $27.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Leerink Partners cut their price target on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a report on Wednesday, April 30th. The Goldman Sachs Group upped their price target on shares of Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Morgan Stanley upped their target price on shares of Pfizer from $31.00 to $32.00 and gave the stock an "equal weight" rating in a research note on Wednesday, April 30th. Finally, BMO Capital Markets dropped their target price on shares of Pfizer from $36.00 to $30.00 in a research note on Thursday, April 17th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $28.55.

Pfizer Stock Down 0.1%

NYSE:PFE traded down $0.02 during midday trading on Wednesday, reaching $24.59. 44,174,346 shares of the stock traded hands, compared to its average volume of 41,887,818. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The business has a 50-day moving average of $23.95 and a two-hundred day moving average of $24.77. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The stock has a market capitalization of $139.79 billion, a PE ratio of 17.82, a price-to-earnings-growth ratio of 0.92 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The company had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. During the same quarter in the prior year, the company posted $0.82 earnings per share. Pfizer's revenue for the quarter was down 7.8% compared to the same quarter last year. On average, equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 7.00%. Pfizer's payout ratio is 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.